KRYS
Krystal Biotech, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
37.24
PEG
0.29
P/B
6.19
P/S
19.60
EV/EBITDA
42.55
DCF Value
$577.66
FCF Yield
2.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.6%
Operating Margin
41.5%
Net Margin
52.6%
ROE
18.7%
ROA
15.4%
ROIC
13.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $107.1M | $51.4M | $1.70 |
| FY 2025 | $389.1M | $204.8M | $6.84 |
| Q3 2025 | $97.8M | $79.4M | $2.66 |
| Q2 2025 | $96.0M | $38.3M | $1.29 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.54
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.